An Observational Multicenter Clinical Study To Assess The Safety And Effectiveness Of The OMNI® Surgical System In Pseudophakic Eyes With Primary Open Angle Glaucoma (ORION 2.0)
Completed · NCT04872348
Conditions: Glaucoma, Open-Angle
At a glance
- Research payments reported, 2025
- $2,635
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 28
About the trial
- Sponsor
- Sight Sciences, Inc.
- Tested
- OMNI® Surgical System (device)
- Dates
- Started 2021-07-01; completion 2023-11-02
- Results posted
- Yes
The purpose of this study is to evaluate the safety and effectiveness of the OMNI® Surgical System in subjects who have undergone canaloplasty and trabeculotomy using OMNI® Surgical System without any concomitant surgery in pseudophakic eyes with mild to moderate primary open angle glaucoma (POAG) at least 150 days prior to enrollment.
From ClinicalTrials.gov, last updated 2025-05-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sight Sciences, Inc. reported $2,635 in research payments for this study in 2025 (2 payments).
Products named: Omni Surgical System
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Constance O. Okeke, MD Ophthalmology · Norfolk, VA
- Anthony Realini, M.D. Ophthalmology · Morgantown, WV
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Hypotony Holdings LLC $2,500
- Virginia Eye Consultants Inc $135
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.